Barclays Reiterates Underweight Rating for Galapagos (NASDAQ:GLPG)

Galapagos (NASDAQ:GLPG - Get Free Report)'s stock had its "underweight" rating restated by equities research analysts at Barclays in a research report issued to clients and investors on Thursday,Benzinga reports.

A number of other research analysts have also weighed in on the stock. Kepler Capital Markets lowered shares of Galapagos from a "hold" rating to a "reduce" rating in a research note on Wednesday, November 20th. Royal Bank of Canada decreased their price target on shares of Galapagos from $32.00 to $30.00 and set a "sector perform" rating on the stock in a research note on Friday, November 1st. Finally, TD Cowen lowered shares of Galapagos from a "strong-buy" rating to a "strong sell" rating in a research note on Thursday, January 9th. Four equities research analysts have rated the stock with a sell rating and six have assigned a hold rating to the stock. According to MarketBeat.com, Galapagos currently has a consensus rating of "Hold" and a consensus target price of $30.75.

Galapagos Trading Down 0.9 %

Shares of GLPG stock traded down $0.22 during mid-day trading on Thursday, hitting $23.71. 198,658 shares of the stock were exchanged, compared to its average volume of 283,764. The firm has a fifty day moving average of $26.70 and a 200 day moving average of $27.45. Galapagos has a 52-week low of $23.45 and a 52-week high of $40.34.

Institutional Trading of Galapagos

A number of hedge funds and other institutional investors have recently made changes to their positions in GLPG. R Squared Ltd acquired a new stake in Galapagos in the 4th quarter valued at approximately $26,000. GAMMA Investing LLC increased its holdings in Galapagos by 140.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 736 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Galapagos by 63.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company's stock valued at $112,000 after purchasing an additional 1,510 shares during the last quarter. Rhumbline Advisers increased its holdings in Galapagos by 21.6% in the 2nd quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company's stock valued at $113,000 after purchasing an additional 814 shares during the last quarter. Finally, Signaturefd LLC increased its holdings in Galapagos by 65.6% in the 3rd quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company's stock valued at $185,000 after purchasing an additional 2,541 shares during the last quarter. Institutional investors and hedge funds own 32.46% of the company's stock.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.